As research tools improve, our use of them must evolve too – we’re here to help 30 Jun 2023 Professor Paul Workman discusses the increased numbers of high-quality chemical tools available to study specific proteins in biomedical research, and what needs to be done to ensure they are used appropriately by biomedical researchers. Chemical probes, usually inhibitors, are getting better and better – and researchers using them need to catch up. Find out more Show/Hide
Reflecting on DeepMind’s AlphaFold artificial intelligence success – what’s the real significance for protein folding research and drug discovery? 13 Aug 2021 In a long read, Professor Paul Workman, Chief Executive and President of the ICR, and also a drug discovery scientist, reflects on the significance of the latest version of AlphaFold – a powerful AI system that has been applied to predict structures for almost 99% of human proteins – for fundamental research and drug discovery. Find out more Show/Hide
Funding cuts create perfect storm that could capsize cancer research in the UK 29 Mar 2021 The UK’s science budget faces catastrophic cuts – on top of the alarming impact of Covid-19 on medical research organisations. Professor Paul Workman, Chief Executive of the ICR, warns that without a change in course from the Government, cancer research in the UK is heading for a perfect storm with an impact that could last decades. Find out more Show/Hide
Climbing the peaks of drug discovery – tackling the most challenging targets with ingenuity and realism 21 Oct 2020
Book published in tribute to the late Dr Susan Lindquist – HSF1 and Molecular Chaperones in Biology and Cancer 24 Apr 2020
Understanding the off-target effects of cancer drugs – and how they could lead us to new forms of treatment 03 Mar 2020
Our manifesto for cancer drug discovery and development – focusing on innovation to tackle treatment resistance and meeting patients’ needs 30 Apr 2019